Mammary Carcinoma Update 2019 - A continuing education series from the MCI Academy

Prof. Dr. med. Volkmar Müller would like to invite you to Hamburg for an interactive and up-to-date event on June 22nd. The treatment of patients with breast cancer has developed dramatically in recent years. In addition to the progression of treatment in the established subgroups (hormone receptor and HER2 status), there are now therapies that are based on individual molecular characteristics, such as the PARP inhibitor therapy in BRCA mutant patients. In addition, tests are under development to establish additional markers within subgroups to predict the efficacy of therapy.

Termin: 

22.06.2019 -  22.06.2019